Hyperliquid Strategies Inc. (PURR)
| Market Cap | 421.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 127.03M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 584,746 |
| Open | 3.360 |
| Previous Close | 3.370 |
| Day's Range | 3.259 - 3.460 |
| 52-Week Range | 3.150 - 4.650 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 5.00 (+50.6%) |
| Earnings Date | n/a |
About PURR
Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York. [Read more]
Analyst Summary
According to one analyst, the rating for PURR stock is "Buy" and the 12-month stock price target is $5.0.
News
Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Hyperliquid Strategies Inc (NASDAQ: PURR) (“HSI” or the “Company”) announced today that its Board of Directors has authorized a stock repurchase program of ...
Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'
Hyperliquid Strategies Inc. chairman Bob Diamond and Hyperliquid Stategies Inc. CEO David Schamis comment on the future of Hyperliquid Strategies Inc. on ‘The Claman Countdown.'
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR” Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wedn...
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting of stockh...
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patie...
Sonnet to Present at the MedInvest Biotech & Pharma Conference
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete...
Sonnet Releases Virtual Investor "What This Means" Segment
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
Sonnet BioTherapeutics Inc. SONN stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm.
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Combined company expected to become largest U.S.-based publicly listed company to hold HYPE ...
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting...
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ®)
Sonnet Announces Release of Corporate Update Video
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete...
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targete...
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy...
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with un...
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ®) p...
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drug...
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs...
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, an...
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Live webcast on Wednesday, January 29 th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-sta...
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ®) with...